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Abstract
Prosthetic joint implantations have revolutionized orthopedic medicine by allowing
individuals to regain physical function with minimal side effects. However, they are susceptible
to post- surgical complications due to bacterial infections. Three significant bacteria that are
responsible for the development of joint infections include Staphylococcus epidermidis,
Staphylococcus aureus, and Pseudomonas aeruginosa, which act by adhering to the prosthesis
and form biofilms thus becoming antibiotic-resistant. It has been reported that green tea
polyphenols, which are extracted from the leaves of the Camellia sinensis plant, have
antibacterial, antioxidant, and anti- inflammatory properties. The purified, and modified
epigallocatechin-3-gallate-stearate (EGCGS) and palmitoyl-epigallocatechin-3-gallate (P-EGCG)
are more efficient and have shown their synergistic effect on antibiotics indicating they could
potentially play a positive role in the elimination of infection. In this study, the inhibitory effect
of EGCG-S and P-EGCG with or without two antibiotics (Bacitracin or Polymyxin B) on the
three most prominent bacteria was investigated. Colony-forming unit (CFU) assays were used to
determine the percent of inhibition by the tea polyphenols. Time course studies were performed
using CF1 and CF2 formulations to determine the percent of inhibition. Congo Red assays were
used to analyze the effect of tea polyphenols on biofilm. Crystal violet quantitative biofilm
assays were used to analyze the effect of tea polyphenols on the percent of biofilm inhibition.
This study showed that EGCG-S and P-EGCG, when used in combination with Bacitracin or
Polymyxin B resulted in the best antibacterial effect and could be used as a treatment against
bacteria that cause joint infections. CF1 and CF2 formulations are also promising treatment
options.
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Introduction
We utilize our joints daily to perform activities such as running, walking, climbing stairs
among many other functions (Etoundi, Semasinghe, Agrawal, Dobner & Jafari, 2021). A joint is
the point of connection where two bones meet and allow for locomotion as well as stability
(Voss & Montavon, 2009). Over time, the daily activities that we partake in can cause joint
diseases where the cartilage and bones of our joints are torn and damaged as well as ligaments
becoming weak (Bullock et al., 2018). Some joint related diseases are osteoarthritis and
rheumatoid arthritis (Bullock et al., 2018). Osteoarthritis is a degenerative joint disease that
affects 25% of adults (Chen et al., 2017). In osteoarthritis, there is the destruction and
progressive loss of cartilage, inflammation of the synovium and the degeneration of the
ligaments (Chen et al., 2017). An individual with this disease can have joint instability, chronic
pain and stiffness around the joints (Chen et al., 2017). Rheumatoid arthritis is an autoimmune
inflammatory disease that starts off by affecting small joints, later progressing to bigger joints
(Bullock et al., 2018). In this disease, bone erosion as well as deformities caused by joint damage
can result (Bullock et al., 2018). Treatments for osteoarthritis and rheumatoid arthritis are aimed
to maximize the function of joints, decrease inflammation, and reduce pain (Bullock et al.,
2018).
Joint artificial replacement surgery with prosthetic implants has restored mobility in
millions of people that have arthritis (Hench, 2005). In 2009, over 905,000 joint replacement
surgeries have been performed in the US and osteoarthritis is ranked as the fourth most common
cause of hospitalization (Song et al., 2013). A disadvantage of joint replacement surgery is that it
can cause bacterial infections, caused by septic or aseptic failure, that are difficult to treat solely
with antibiotic treatment (Song et al., 2013; Kasch et al., 2017). Bacterial infections can be
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categorized into three categories which include early, delayed, or late onset of symptoms after a
joint prosthetic implant. Early infections normally occur within three months from when an
individual got a prosthetic joint implant put in. Delayed infections can occur from three months
after the joint implant surgery up until two years, while late infections are those that occur more
than two years from the surgery (Tande & Patel, 2014).
The main pathogens that cause these bacterial infections are gram-positive bacteria, but
gram-negative bacteria can also cause these infections (Rodriguez-Merchan & Liddle, 2018).
Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis are the main
three pathogens that cause prosthetic joint infection. These bacteria are opportunistic in the terms
that they are able to stick to materials like titanium, polymethylmethacrylate cement and cobaltchromium, which are used to make prosthetic joint implants and, in the process, form a layer of
biofilm to protect itself (Song et al., 2013; Davidson et al., 2019). The formation of biofilm is
where bacterial cells are enclosed in a matrix that is primarily made up of nucleic acids,
polysaccharides and proteins (Fey & Olson, 2010). Biofilm is formed in four main steps
including the adherence of the bacterial cell, growth and accumulation of the bacterial cells,
biofilm maturation, and finally detachment (Fey & Olson, 2010). Bacteria use quorum sensing in
order to respond to gene expression changes that therefore allow biofilm to form (Trampuz &
Zimmerli, 2005). Quorum sensing can also lead to transcriptional changes which produce genes
for antibiotic resistance and virulence (Davidson et al., 2019; Nana et al., 2016). Gram-positive
bacteria use autoinducing peptides as their quorum sensing system (Rutherford & Bassler, 2012).
Gram-negative bacteria use autoinducers, which are extracellular signaling molecules to
communicate with one another (Rutherford & Bassler, 2012). Protease and elastase are two
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virulence factors that these three bacteria produce and they help in the process of quorum sensing
to form biofilm and have the ability to cause tissue damage (Maeda, 1996).
While 1 to 2 percent of prosthetic joint implants lead to bacterial infections, this is cause
for concern because it is associated with expensive medical costs, high rates of morbidity and
can possibly lead to implant failure (Ribeiro et al., 2012). Treating these bacterial infections
usually involves antimicrobial therapy, debridement, or irrigation with antiseptic solution (wash).
There are two main problems with these treatments approaches which include that the bacteria
can become antibiotic resistant and that the bacteria are able to form biofilm as a defense
mechanism and therefore causing the infection to get bigger. Alternative approaches have been
researched, one of which is green tea polyphenols. Green tea polyphenols, which are extracted
from the leaves of the Camellia sinensis plant have anti-microbial, anti-inflammatory, and antioxidant properties that can inhibit infectious agents and be helpful in treating infections
(Reygaert, 2018). Catechins are major tea polyphenols that are found in green tea (Wu & Brown,
2021), which contribute to green tea’s health beneficial properties. There are four main types of
catechins including epigallocatechin-3-gallate (EGCG), epicatechin (EC), epigallocatechin
(EGC) and epicatechin-3-gallate (ECG) (Cabrera, Artacho & Gimenez, 2006). Epigallocatechin3-gallate (EGCG) makes up about 59 percent of the catechins (Cabrera, Artacho & Gimenez,
2006).
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Studies have shown that epigallocatechin-3-gallate (EGCG) can inhibit the growth of
bacteria (Taylor, Hamilton-Miller & Stapleton, 2005). EGCG has antimicrobial and bactericidal
effects on both gram-positive and gram-negative bacteria (Wu & Brown, 2021). EGCG binds to
the cell membrane of the bacteria and damages it. This damage to the cell membrane inhibits the
ability of the bacteria to bind to host cells as well as inhibiting bacteria to attach to one another to
form biofilms, which are important for pathogenesis of bacteria (Reygaert, 2014). EGCG is
known to synergistically work together with antibiotics and brings forth an encouraging
approach to treat antibiotic resistant strains of bacteria (Reygaert, 2018; Wu & Brown, 2021).
Since EGCG is not stable, modified lipophilic palmitoyl-epigallocatechin-3-gallate (P-EGCG)
and epigallocatechin-3-gallate stearate (EGCG-S) have been used and reported to have
promising antimicrobial activity (Liu, Kang & Yan, 2021). Recently, several reports suggested
that EGCG-S and P-EGCG can enhance the activities of different antibiotics (Yussof et al.,
2019). In addition, these tea polyphenols have also displayed antibiofilm activities in many
Gram-positive and Gram-negative bacteria (Shinde et al., 2021). The process of making optimal
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P-EGCG containing formulations are underway. Two most advanced formulations CF1, a gel
form and CF2, in a solution form are established (Chu et al., 2020). The effect of P-EGCG,
EGCG-S and the new formulations (CF1 and CF2) containing P-EGCG will be used to evaluate
their effect on the joint infecting bacteria and further develop organic antimicrobial agents to
combat the major microorganisms and prevent joint infection.
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Objectives of this Study
The objectives of this study are:
1. Characterization of the three bacteria: Pseudomonas aeruginosa, Staphylococcus aureus,
and Staphylococcus epidermidis.
2. Study the synergistic effect of EGCG-S and P-EGCG with antibiotics/wash on
Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis.
3. Evaluate CF1 and CF2 formulations as antibacterial agents.
4. Examine the possible synergistic effects that EGCG-S and P-EGCG with antibiotics/wash
have on biofilm formation.
I.
II.

Congo Red Qualitative Biofilm Assay
Crystal Violet Quantitative Biofilm Assay
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Materials and Methods
1. Bacterial Cultures
Three bacteria were used: Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus
(S. aureus), and Staphylococcus epidermidis (S. epidermidis). The bacterial cultures were
maintained on nutrient agar (NA) plates and/or in nutrient broth. The nutrient agar plates
were stored in the refrigerator at 4Ԩ. For every experiment, fresh overnight cultures were
made from the stock plates. The overnight cultures were made by taking a small amount of
the bacteria from the stock plates using a inoculating loop or cotton swab and placing the
bacteria into a falcon tube containing nutrient broth (NB). The falcon tubes containing the
bacteria and nutrient broth were labeled with the name of the bacteria, the date and the
initials of the person performing the experiment. They were left to incubate overnight at 250
rpm and 37Ԩ. The next day, the overnight culture was removed from the incubator.
2. Media Preparation
The media used for the experiments performed in this study were Nutrient Broth and Nutrient
Agar. The nutrient broth was prepared as follow: 8 grams of media was mixed with 1 Liter of
distilled water. The nutrient agar was prepared as follows: 23 grams of the media from Difco
was mixed with 1 Liter of distilled water in a 2 Liter flask. After the media was mixed and
dissolved, it was autoclaved at 121Ԩ for 30 minutes and set to the liquid cycle setting. When
the nutrient broth and nutrient agar were done being autoclaved, the nutrient broth was
cooled at room temperature, followed by being stored in the -4Ԩ cold room. The nutrient
agar, after being autoclaved was cooled down at room temperature and poured intro petri
dishes aseptically.
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3. Gram Stain
Gram staining was performed to make sure that the bacterial culture is pure and not
contaminated. It was also used to determine the morphological characteristics of the bacteria.
A sterile cotton swab was used to take some bacteria from the stock plate and then smeared
onto a sterile microscope slide. The microscope slide containing the bacterium sample was
dried and heat fixed. Crystal violet was applied to the slide for 20 seconds and then rinsed off
with deionized water for 2 seconds. Gram’s iodine was added to the slide for 1 minute, and
then washed off with Gram’s decolorizer for 10 seconds. The decolorizer was rinsed off with
deionized water for 2 seconds. Safranin was used to counter-stain the slide and applied for 1
minute. After 1 minute, the safranin was rinsed off the slide with deionized water. A cover
slip was then put on the slide and the slide was dried with bibulous paper. Using a light
microscope, the bacteria sample was then observed at 1000x total magnification (Lee et al.,
2015).
4. Preparation of Treatments
a. Tea Polyphenols
EGCG-S and P-EGCG were purchased from Camellix LLC, Augusta, GA. A stock of 10X
250 ߤg/mL was prepared. The EGCG-S and P-EGCG compounds were dissolved in 200
proof ethanol. The stocks were then stored in a -20Ԩ freezer. Below is the calculation of the
stock and the dilution:
250 ߤg/mL= 0.00025 grams of compound + 1 mL of EtOH/H2O
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b. Antibiotics
The powders for Polymyxin B and Bacitracin, which were the two antibiotics used in this
study were purchased from Sigma Aldrich. Polymyxin B and Bacitracin were made at 100X
stock concentrations at 1.98 mg/mL and 22.5 mg/mL, respectively. Polymyxin B was made
at 10X using 100 ߤL from the 100X stock of 1.98 mg/mL Polymyxin B and diluting it with
900 ߤL of 200 proof Ethanol. Bacitracin was made at 10X using 100 ߤL from the 100X stock
of 22.5 mg/mL and diluting it with 900 ߤL of 200 proof Ethanol. The antibiotics were stored
in the -20Ԩ freezer.
c. Wash
The wash that was used was prepared by mixing 10 mL of 0.9% saline with 1.57 mL of
0.25% sodium hypochlorite and 0.3 mL povidone iodine (Dynarex).
d. Combination Treatments
Combination Treatments were prepared as followed:

EGCG-S+Wash: 100 ߤL of 250 ߤg/mL EGCG-S + 900 ߤL of Wash
EGCG-S+ Polymyxin B: 100 ߤL of 250 ߤg/mL EGCG-S + 10 ߤL of 100X Polymyxin B
EGCG-S+ Bacitracin: 100 ߤL of 250 ߤg/mL EGCG-S + 10 ߤL of 100X Bacitracin
Wash+Polymyxin B: 990 ߤL of Wash + 10 ߤL of 100X Polymyxin B
Wash+Bacitracin: 990 ߤL of Wash + 10 ߤL of 100X Bacitracin
Polymyxin B+Bacitracin: 10 ߤL of 100X Polymyxin B + 10 ߤL of 100X Bacitracin + 980
ߤL Saline
EGCG-S+ Wash+Polymyxin B: 100 ߤL of 250 ߤg/mL EGCG-S + 890 ߤL of Wash + 10 ߤL
of 100X Polymyxin B
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EGCG-S+ Wash+Bacitracin: 100 ߤL of 250 ߤg/mL EGCG-S + 890 ߤL of Wash + 10 ߤL
of 100X Bacitracin
EGCG-S+ Polymyxin B+Bacitracin: 100 ߤL of 250 ߤg/mL EGCG-S + 10 ߤL of 100X
Polymyxin B + 10 ߤL of 100X Bacitracin
Wash+Polymyxin B+Bacitracin: 980 ߤL of Wash + 10 ߤL of 100X Polymyxin B+ 10 ߤL
of 100X Bacitracin
EGCG-S+ Wash+Polymyxin B+Bacitracin: 100 ߤL of 250 ߤg/mL EGCG-S + 880 ߤL of
Wash + 10 ߤL of 100X Polymyxin B + 10 ߤL of 100X Bacitracin
P-EGCG+ Wash: 100 ߤL of 250 ߤg/mL P-EGCG + 900 ߤL of Wash
P-EGCG+ Polymyxin B: 100 ߤL of 250 ߤg/mL P-EGCG + 10 ߤL of 100X Polymyxin B
P-EGCG+ Bacitracin: 100 ߤL of 250 ߤg/mL P-EGCG + 10 ߤL of 100X Bacitracin
P-EGCG+ Wash+Polymyxin B: 100 ߤL of 250 ߤg/mL P-EGCG + 890 ߤL of Wash + 10
ߤL of 100X Polymyxin B
P-EGCG+ Wash+Bacitracin: 100 ߤL of 250 ߤg/mL P-EGCG + 890 ߤL of Wash + 10 ߤL
of 100X Bacitracin
P-EGCG +Polymyxin B+Bacitracin: 100 ߤL of 250 ߤg/mL P-EGCG + 10 ߤL of 100X
Polymyxin B + 10 ߤL of 100X Bacitracin
P-EGCG+ Wash+Polymyxin B+Bacitracin: 100 ߤL of 250 ߤg/mL P-EGCG + 880 ߤL of
Wash + 10 ߤL of 100X Polymyxin B + 10 ߤL of 100X Bacitracin

After the combination treatments were prepared, they were used for Colony-forming unit
(CFU) Assays, which were treated for 30 seconds to 5 minutes. Overnight cultures of the
bacteria were prepared. 10 ߤ ܮof overnight culture was put into an eppendorf tube for each
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treatment. To the eppendorf tube, 90 ߤ ܮof treatment was added and the eppendorf tube was
vortexed for 10-15 seconds. The eppendorf tubes were then treated for 30 seconds and 5
minutes. After the treatment time of either 30 seconds or 5 minutes, 25ߤ ܮwas taken out of
the eppendorf tube and plated out on nutrient agar X plates. The nutrient agar X plates were
then incubated overnight and then next day, the colonies on the X plates were counted. The
percent of inhibition was calculated as follows:

% Inhibition= ((Control CFU-Treated CFU)/Control CFU)) X 100

Log Reduction was also calculated as follows:
Log Reduction= log(Control CFU/Treated CFU)

5. Congo Red Qualitative Biofilm Assay Experiment
To study the effects of antibiotics and tea polyphenols on biofilm formation, congo red
assays were performed. Overnight cultures of the bacteria were made. Treatment of Biofilm
formation: 5 ߤL of the respective overnight culture was mixed with 45 ߤL of treatment in
micro-centrifuge tubes and treated for 5 minutes. After 5 minutes, 25 ߤL was plated in its
respective well. The plate was placed in the incubator at 37Ԩ for two days, followed by
analysis.
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EGCG-S P-EGCG (250
(250 ug/mL)
ug/mL)
EGCG-S+
Polymyxin B

EGCG-S+
Wash+
Polymyxin B

EGCG-S+
Wash+
Bacitracin

Blank

P-EGCG+
Polymyxin B

P-EGCG+
Wash+
Polymyxin B+
Bacitracin

Bleach

EGCG-S+
Bacitracin
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Wash

Polymyxin B
(1.98 mg/mL)

Bacitracin
(22.5 mg/mL)

Wash+
Polymyxin B

Wash+
Bacitracin

Polymyxin B+
Bacitracin

EGCG-S+
Wash+
EGCG-S+
Wash+
Polymyxin B+ Polymyxin Polymyxin B+
Bacitracin
Bacitracin B+ Bacitracin

P-EGCG+
Wash

P-EGCG+
Wash+
Polymyxin B

P-EGCG+
Polymyxin B+
Bacitracin

P-EGCG+
Bacitracin

P-EGCG+
Wash+
Bacitracin

Diagram 1: Plate set up of Congo Red assay

6. Crystal Violet Quantitative Biofilm Assay Experiment
To study the effect of tea polyphenols, antibiotics and CF1/CF2 formulations on biofilm
formation, crystal violet assays were performed. Overnight cultures of the bacteria were
made. The samples were prepared in micro-centrifuge tubes according to the following
template:
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Treatment: EGCG-S (250 ࣆg/mL)

Treatment: EGCG-S (250 ࣆg/mL)

600 ߤL of TSB + 300 ߤL of Overnight

+Polymyxin B (10X)

Culture + 100 ߤL of Treatment

600 ߤL of TSB + 300 ߤL of Overnight
Culture + 100 ߤL of Treatment

Treatment: Bacitracin (10X)

Treatment: EGCG-S (250 ࣆg/mL)

600 ߤL of TSB + 300 ߤL of Overnight

+Polymyxin B (10X) +Bacitracin (10X)

Culture + 100 ߤL of Treatment

600 ߤL of TSB + 300 ߤL of Overnight
Culture + 100 ߤL of Treatment

Treatment: Polymyxin B (10X)

Treatment: CF1

600 ߤL of TSB + 300 ߤL of Overnight

600 ߤL of TSB + 300 ߤL of Overnight

Culture + 100 ߤL of Treatment

Culture + 100 ߤL of Treatment

Treatment: EGCG-S (250 ࣆg/mL) +

Treatment: CF2

Bacitracin (10X)

600 ߤL of TSB + 300 ߤL of Overnight

600 ߤL of TSB + 300 ߤL of Overnight

Culture + 100 ߤL of Treatment

Culture + 100 ߤL of Treatment
Treatment: Bleach

Treatment: P-EGCG (250 ࣆg/mL)

600 ߤL of TSB + 300 ߤL of Overnight

600 ߤL of TSB + 300 ߤL of Overnight

Culture + 100 ߤL of Treatment

Culture + 100 ߤL of Treatment

Diagram 2: Set up of Crystal Violet Experimental Plate
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Negative
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Tetracycline

Negative
Control:
EGCG-S+
Bacitracin
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EGCG-S+
Polymyxin
B

900 ߤL TSB
+ 100 ߤL
EGCG-S+
Tetracycline

900 ߤL TSB +
100 ߤL
EGCG-S+
Bacitracin

900 ߤL TSB
+ 100 ߤL
EGCG-S+
Polymyxin B
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Negative
Control:
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Diagram 3: Set up of Crystal Violet Control/Negative Control Plate
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The plates were labeled with date and placed into the incubator at 37Ԩ for 4 days (Nowak et
al., 2015). On the fourth day, the plates were aspirated, washed with 1X PBS, and aspirated
(Nowak et al., 2015). The wells were stained with 0.1% crystal violet solution and left to sit
for 30 minutes (Nowak et al., 2015). After 30 minutes, the wells were aspirated, then washed
with 1X PBS, aspirated followed by the plates being inverted overnight to dry (Nowak et al.,
2015). Once dry, sterile cotton swabs were used to remove excess dye on the sides of wells
using 30% acetic acid (Nowak et al., 2015). Then, 1 mL of 30% acetic acid was added to
each well and the plates were swirled 3-4 times to lift the attached cells and/or the biofilm
(Nowak et al., 2015). The absorbance was performed at 595nm with 30% acetic acid being
used as a blank (Nowak et al., 2015). The percent of biofilm inhibition was calculated as
follows:

% of Biofilm Inhibition= ((control OD595-treated OD595)/control OD595) X 100
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Results
This study consisted of the use of three microorganisms: Gram-negative Bacteria: Pseudomonas
aeruginosa (P. aeruginosa); and Gram-positive Bacteria: Staphylococcus aureus (S. aureus) and
Staphylococcus epidermidis (S. epidermidis). These three bacteria are known to be the main
bacteria involved in the pathogenesis of prosthetic joint infections. Various experiments were
performed to establish the potential uses of EGCG-S and P-EGCG tea polyphenols with
antibiotics. Prosthetic joint implants are associated with a 1-2 percent risk of acquiring a
bacterial infection (Ribeiro et al., 2012). Sometimes the bacterial infection is also the reason for
the removal of the prosthetic joint. Current treatment methods to treat bacterial infections include
antibiotic therapy with Polymyxin B or Bacitracin, debridement, or irrigation with wash. There
are two main problems with this current treatment. First, bacteria are able to become resistant to
the antibiotics. This can happen when bacteria produce efflux pumps that are able to decrease the
concentration of the antibiotic inside the bacterial cell, therefore causing the antibiotic to become
less efficient and not able to reach its target (Lin et al., 2015). Bacteria are also able to produce
antibiotic resistance enzymes, which can change the conformation of antibiotics and make them
inactive (Lin et al., 2015). The second problem with the current treatment method is that bacteria
can form biofilm as a defense mechanism, which protects the bacteria from the antibiotic therapy
(Hollmann et al., 2014). In this study, different approaches were used to evaluate and profile the
effect that EGCG-S and P-EGCG have on the different steps of the current treatments to
establish the most critical step (s) where the tea polyphenols can combat this problem. In
addition, the newly formulated P-EGCG containing formulations CF1 and CF2 were also used to
evaluate their effect on these three bacteria.
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1. Characterization of the three bacteria: Pseudomonas aeruginosa, Staphylococcus aureus,
and Staphylococcus epidermidis.

A. Pseudomonas aeruginosa
A gram stain is a technique in which bacteria can be classified into two groups, either
being Gram-positive or Gram-negative. It is important to distinguish which bacteria are
Gram-positive and which bacteria are Gram-negative because different bacteria need to
be treated in different ways depending on their characteristics. The gram stain of P.
aeruginosa is shown in Figure 1, which shows that P. aeruginosa is an aerobic, rodshaped bacterium. In Figure 1, the pink stained cells in the gram stain indicate that P.
aeruginosa is a gram-negative bacterium.

JOINT INFECTIONS: EGCG-S AND BACTERIA

28

Figure 1: Gram Stain of P. aeruginosa under the light microscope at 1000x under oil
immersion. P. aeruginosa displaying gram-negative characteristics.
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B. Staphylococcus aureus
Figure 2 shows a gram stain of Staphylococcus epidermidis. Staphylococcus epidermidis
is a gram-positive bacterium that is purple in color. It is an aerobic, cocci shaped
bacterium in regard to its morphology.

Figure 2: Gram stain of S. aureus under the light microscope at 1000X under oil
immersion. S. aureus displaying gram-positive characteristics.
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C. Staphylococcus epidermidis
Figure 3 shows a gram stain of Staphylococcus epidermidis. Staphylococcus epidermidis
is a gram-positive bacterium that is purple in color. It is an aerobic, cocci shaped
bacterium in regard to its morphology.

Figure 3: Gram stain of S. epidermidis under the light microscope at 1000X under oil
immersion. S. epidermidis displaying gram-positive characteristics.

Summary: The Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus
epidermidis bacterial cultures are pure and homogeneous. DNA extraction and
sequencing was performed to confirm the identity of the bacteria (data not shown).
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2. Study the synergistic effect of EGCG-S and P-EGCG with antibiotics/wash on
Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis.

This was performed to profile all of the possible treatment combinations and evaluate
which treatments are the best combinations in terms of inhibition and efficacy.

A. Pseudomonas aeruginosa
An overnight culture for P. aeruginosa was prepared to see how various treatments affect the
inhibition of P. aeruginosa. Figure 4 shows that when P. aeruginosa is treated with EGCG-S
and antibiotics at the same time, the percent of inhibition is 100 percent, regardless of if one
antibiotic is used or both antibiotics.

Percent Inhibition (%)

Inhibition of Pseudomonas aeruginosa after
EGCG-S and Antibiotic Combination Treatments
100
100

100

100

100

100

100

75
50
25
0

Treatment

30 sec

5 min

Figure 4: Inhibition of Pseudomonas aeruginosa after EGCG-S and Antibiotic Combination
treatments.
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Figure 5 shows a bar representing the inhibition of P. aeruginosa growth after various
treatments, which included the tea polyphenol P-EGCG, Polymyxin B and Bacitracin.
Regardless of if P. aeruginosa was treated with P-EGCG and one antibiotic or both
antibiotics, all of the treatments resulted in a percent inhibition of 100 percent.

Percent Inhibition (%)

Inhibition of Pseudomonas aeruginosa after
P-EGCG and Antibiotic Combination
Treatments
100
75

100

100

100

100

100

100

50
25
0

Treatment
30 sec

5 min

Figure 5: Inhibition of Pseudomonas aeruginosa after P-EGCG and Antibiotic Combination
treatments.

When EGCG-S, antibiotics Polymyxin B and Bacitracin as well as wash are used together to
treat P. aeruginosa, there is 92.690 percent of inhibition as shown in Figure 6. The treatment
EGCG-S plus wash and Polymyxin B resulted in the lowest percent of inhibition at 82.915
percent compared to the other three treatments that had higher inhibition percentages. The
percent inhibition increased slightly by 6 percent when both Polymyxin B and Bacitracin
were added to the EGCG-S+Wash combination treatment.
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Percent of Inhibition (%)

Inhibition of Pseudomonas aeruginosa after
EGCG-S, Wash and Antibiotic Combination
Treatments
100
75

86.835

88.925

82.915

92.690

50
25
0

Treatment

Figure 6: Inhibition of Pseudomonas aeruginosa after EGCG-S, Wash and Antibiotic
Combination Treatments.

Figure 7 shows the inhibition of P. aeruginosa after it is treated with P-EGCG, Polymyxin B,
Bacitracin, and wash in different combinations. For all the treatments shown in Figure 11, the
inhibition percentage for P. aeruginosa ranges from 82.370 percent to 85.790 percent, with
the P-EGCG, wash, and Bacitracin combination treatment displaying the highest percent of
inhibition.
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Inhibition of Pseudomonas aeruginosa after
P-EGCG, Wash and Antibiotic Combination
Treatments
Percent Inhibition (%)

100.000
75.000

85.570

82.370

85.790

50.000

25.000
0.000

Treatment

Figure 7: Inhibition of Pseudomonas aeruginosa after P-EGCG, Wash and Antibiotic
Combination Treatments.

B. Staphylococcus aureus
An overnight culture of S. aureus was prepared to see how different treatments affect the
inhibition of S. aureus. When S. aureus is treated with EGCG-S and antibiotics together, as
shown in Figure 8, the results are the same as seen for P. aeruginosa. It does not matter if S.
aureus is treated with EGCG-S and one antibiotic or with two antibiotics, the percent of
inhibition is constant at 100 percent.
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Percent Inhibition (%)

Inhibition of Staphylococcus aureus after
EGCG-S and Antibiotic Combination
Treatments
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5 min

Figure 8: Inhibition of Staphylococcus aureus after EGCG-S and Antibiotic Combination
Treatments.

Figure 9 shows that when S. aureus is treated with P-EGCG with a single antibiotic, either
being Polymyxin B or Bacitracin, or with both antibiotics, the inhibition of S. aureus is
similar around 100 percent.
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Percent Inhibition (%)
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P-EGCG and Antibiotic Combination
Treatments
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Figure 9: Inhibition of Staphylococcus aureus after P-EGCG and Antibiotic
Combination Treatments.

Regardless of whether S. aureus is treated with EGCG-S+Wash alone or with the two
antibiotics together, the percent of inhibition was very similar. When S. aureus is
treated with EGCG-S, Polymyxin B, Bacitracin and wash all combined together, the
bacterium is inhibited by 96.665 percent compared to the 96.775 percent when S.
aureus is just treated with EGCG-S and Wash as shown in Figure 10. The same
results were observed for P-EGCG. Figure 11 shows that when S. aureus is treated
with P-EGCG, Wash and both antibiotics in different combinations, the percentage of
inhibition ranges from 91.025 percent to 94.325 percent. The data shows that the
addition of antibiotics to EGCG-S+ Wash or P-EGCG+ Wash does not really impact
the percent of inhibition towards S. aureus.
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Figure 10: Inhibition of Staphylococcus aureus after EGCG-S, Wash and Antibiotic
Combination Treatments.

Figure 11: Inhibition of Staphylococcus aureus after P-EGCG, Wash and Antibiotic
Combination Treatments.
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C. Staphylococcus epidermidis
An overnight culture of S. epidermidis was prepared. Figure 12 shows that when S.
epidermidis is treated with EGCG-S and antibiotics at the same time for both 30 seconds and
5 minutes, there is 100 percent inhibition, regardless of one antibiotic being used or two.
When P-EGCG, Polymyxin B and Bacitracin were used together to treat S. aureus, it resulted
in a percent inhibition of 99.865 percent regarding the growth of S. epidermidis after 30
seconds of treatment. The percent inhibition increased to 100 percent after 5 minutes of
treatment.

Figure 12: Inhibition of Staphylococcus epidermidis after EGCG-S, P-EGCG and Antibiotic
Combination Treatments.

When EGCG-S, wash, Polymyxin B and Bacitracin were used in different combinations as
treatments against S. epidermidis, they resulted in percent inhibitions ranging from 64.81
percent to 95.66 percent as shown in Figure 13. The highest percentage of inhibition, which
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was 95.66 percent was from the EGCG-S and Wash combination treatment. When P-EGCG,
wash and either of the two antibiotics were combined together, the results were similar for
the percent inhibition, which ranged from 89.53 percent to 93.11 percent as shown in Figure
14.

Figure 13: Inhibition of Staphylococcus epidermidis after EGCG-S, Wash and Antibiotic
Combination Treatments.
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Figure 14: Inhibition of Staphylococcus epidermidis after P-EGCG, Wash and Antibiotic
Combination Treatments.

D. Combination of Bacteria: Pseudomonas aeruginosa+ Staphylococcus aureus +
Staphylococcus epidermidis
After an overnight bacterial culture of P. aeruginosa, S. aureus, and S. epidermidis was
combined together was prepared, different treatments were applied to see how they affect the
inhibition regarding the growth of the combination bacteria. Figure 15 shows that when the
EGCG-S or P-EGCG tea polyphenol is used in different combinations with wash and
antibiotics, the range of inhibition across all of the treatments is 50.490 percent to 65.975
percent. The highest percent of inhibition was when P-EGCG, wash and Polymyxin B were
used together as a treatment and resulted in a 65.975 percent inhibition. EGCG-S with wash
as a treatment worked slightly less at inhibiting the growth of the combination bacteria
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compared to the EGCG-S+ Wash+ Polymyxin B or Bacitracin combination treatment.
Overall, it was shown that it is harder to treat a combination of microorganisms.

Figure 15: Inhibition of Combination Bacteria (P. aeruginosa + S. aureus+ S. epidermidis)
after EGCG-S, P-EGCG, Wash and Antibiotic Combination Treatments.

Summary:
When EGCG-S or P-EGCG is combined with either Polymyxin B or Bacitracin, the percent
inhibition is near 100 percent against each individual bacterium and the combination
bacteria, shown in Figure 17 (outlined in red). Out of all the wash combination treatments,
the EGCG-S+ Polymyxin B+ Bacitracin+ Wash treatment worked the best against
Pseudomonas aeruginosa with a percent inhibition of 92.690 percent. EGCG-S+ Wash
worked well for Staphylococcus aureus and Staphylococcus epidermidis, 96.755 percent and
95.66 percent inhibition respectively. The combination treatments worked to some extent for
the combination bacteria. EGCG-S or P-EGCG combined with single antibiotics got the best
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step was added into the combination treatment, the percent of inhibition was reduced. The
chemical components in the wash may react with the antibiotics or tea polyphenols.

Figure 16: Summary of a combination profiling study using EGCG-S, P-EGCG, Wash,
Polymyxin B and Bacitracin. The table displays how the various treatments affect the
percentage of inhibition. PA: Pseudomonas aeruginosa; SA: Staphylococcus aureus; SE:
Staphylococcus epidermidis; Combo: Pseudomonas aeruginosa+ Staphylococcus aureus+
Staphylococcus epidermidis.
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3. Evaluate CF1 and CF2 formulation as antibacterial agents.

This study was performed to see how P-EGCG containing formulations affect the inhibition
of Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis and if
they can inhibit their growth. A Colony Forming Unit (CFU) Assay was performed using X
plates for a timed study for 30 seconds, 5 minutes and 10 minutes.

A. Pseudomonas aeruginosa
Figure 17 shows a Pseudomonas aeruginosa control plate as well as nutrient agar quad plates
treated with the CF1 and CF2 formulations at different dilutions for 30 seconds, 5 minutes
and 10 minutes. It was shown in Figure 18, that CF1 and CF2 formulations at 10-1 and 10-2
dilutions inhibited Pseudomonas aeruginosa growth up to 99.99945 percent and 99.99971
percent, respectively in as little as 30 seconds of treatment. After being treated for 5 minutes
with either the CF1 or CF2 formulations, the growth of Pseudomonas aeruginosa was
inhibited by 100 percent.
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Figure 17: Pseudomonas aeruginosa CF1 and CF2 Time Course Study. Top row: Pseudomonas
aeruginosa control for 30 seconds, 5 minutes and 10 minutes. Bottom row: Pseudomonas
aeruginosa treated with CF1 and CF2 formulations at 10-1 and 10-2 dilutions.
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Figure 18: Bar graph displaying the percent inhibition of Pseudomonas aeruginosa after
P-EGCG containing CF1 and CF2 Formulation Treatments.

B. Staphylococcus aureus

Figure 19 shows a S. aureus control plate and two nutrient agar plates that were treated with
the CF1 and CF2 formulations at the following times: 30 seconds, 5 minutes, and 10 minutes.
It was shown in Figure 20, that both the CF1 and CF2 formulations inhibited S. aureus
growth 100 percent within 30 seconds of treatment.

JOINT INFECTIONS: EGCG-S AND BACTERIA

46

Figure 19: Staphylococcus aureus CF1 and CF2 Time Course Study. Left to Right:
Staphylococcus aureus control for 30 seconds, 5 minutes and 10 minutes. Staphylococcus
aureus treated with CF1 and CF2 formulations at 10-1 and 10-2 dilutions.

Percent Inhibition (%)

Percent Inhibition of Staphylococcus aureus
after
CF1 and CF2 Treatment
100
75

100

100

100

100

100

100

50

25
0

30 seconds

5 minutes

10 minutes

Treatment Time
CF1

CF2

Figure 20: Inhibition of Staphylococcus aureus after P-EGCG containing CF1 and CF2
Formulation Treatments.
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C. Staphylococcus epidermidis

Figure 21 shows a S. epidermidis control plate as well as nutrient agar plates, which were
treated with the CF1 and CF2 formulations at different dilutions for 30 seconds, 5
minutes and 10 minutes. It was shown in Figure 22 that the CF1 and CF2 formulations at
10-1 and 10-2 dilutions inhibited S. epidermidis growth up to 100 percent in as little as 30
seconds of treatment time.

Figure 21: Staphylococcus epidermidis CF1 and CF2 Time Course Study. The figure
shows the Staphylococcus epidermidis control plate and the two agar plates that were
treated with the CF1 and CF2 formulations at 10-1 and 10-2 dilutions.
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Figure 22: Inhibition of Staphylococcus epidermidis after P-EGCG containing CF1 and
CF2 formulation treatments.

Summary:
Both of the P-EGCG containing formulations, CF1 and CF2 work in inhibiting bacterial
growth of Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus
epidermidis. For P. aeruginosa, 99.99945 percent of bacterial growth is inhibited in 30
seconds after treatment with the CF1 formulation and this treatment is associated with a
log reduction value of 5.7085. The P-EGCG containing CF2 formulation showed similar
results, with a 99.99971 percent of inhibition regarding P. aeruginosa bacterial growth
and a respective log reduction of 5.859. The CF1 and CF2 formulations can inhibit the
bacterial growth of S. aureus and S. epidermidis to 100 percent in as little as 30 seconds
with a log reduction values higher than 5.859. These results indicate that these P-EGCG

JOINT INFECTIONS: EGCG-S AND BACTERIA

49

containing CF1 and CF2 formulations really work with a potent antimicrobial activity
and have the potential to be commercialized.

Figure 23: Summary of P. aeruginosa, S. aureus, and S. epidermidis bacterial growth
inhibition after P-EGCG containing CF1 and CF2 formulation treatments.

4. Examine the possible synergistic effects that EGCG-S and P-EGCG with antibiotics have
on biofilm formation.

This study was performed to see which treatments using EGCG-S and P-EGCG are the
most effective in preventing the bacteria from forming biofilm. If we know which
treatment prevents biofilm, then we can utilize that information with the goal of
overcoming the antibiotic resistance problem that P. aeruginosa, S. aureus, and S.
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epidermidis are associated with. Two different combination profiling studies were done
with various treatments, including a Congo Red Qualitative Biofilm Assay and a Crystal
Violet Quantitative Biofilm Assay.

I.

Congo Red Qualitative Biofilm Assay to Analyze the Effect of Tea Polyphenols
and Antibiotics/wash on Biofilm Formation

A. Pseudomonas aeruginosa

In this study, EGCG-S and P-EGCG tea polyphenols as well as the antibiotics,
Polymyxin B and Bacitracin were used to analyze the inhibition of biofilm formation.
Figure 24 shows a template of how the Congo red plates were set up as well as which
treatments prevented biofilm to form (shown in green). The wells on the plate were
treated with the respective treatments for 5 minutes and are shown in Figure 25. After
the plate was incubated, it was qualitatively analyzed. The results shown in Figure 25
indicate that tea polyphenols EGCG-S and P-EGCG have a considerable synergistic
effect with antibiotics on P. aeruginosa than with either of the antibiotics alone.
Wells 5 and 6, which are treatments Polymyxin B and Bacitracin individually,
respectively are positive for biofilm formation as shown in Figure 25. When
Pseudomonas aeruginosa was treated with the combination of EGCG-S, Polymyxin
B and Bacitracin together, there was no formation of biofilm as shown in well 15.
Wells 19 and 20, which are treatments P-EGCG plus Polymyxin B and P-EGCG plus
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Bacitracin, respectively were negative for biofilm formation. 24 hours after
Pseudomonas aeruginosa was treated with the combination of EGCG-S, wash,
Polymyxin B and Bacitracin, shown by well 17 there was biofilm that formed, shown
in the top two plates of Figure 25. Though, after 48 hours the EGCG-S, wash,
Polymyxin B and Bacitracin combination treatment started decreasing the amount of
biofilm that had formed. This is shown in the bottom two plates of Figure 25, well 17.
EGCG-S, P-EGCG and Wash in combination with single antibiotics (either
Polymyxin B or Bacitracin) or with both antibiotics inhibited biofilm formation in P.
aeruginosa. This was represented by the wells remaining red in color. P. aeruginosa
is biofilm resistant to Polymyxin B.
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Figure 24: Pseudomonas aeruginosa Congo Red Assay plate template. The green
represents the wells which are biofilm negative and do not allow Pseudomonas
aeruginosa to form biofilm with those respective treatments.
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Figure 25: Pseudomonas aeruginosa Congo Red Qualitative Biofilm Assay.
Pseudomonas aeruginosa was treated with various treatments for 5 minutes, as listed
in Figure 24. Top two plates: Congo Red plate 24 hours after treatment. Left: front
of the plate. Right: back of the plate. Bottom two plates: Congo Red plate 48 hours
after treatment. Left: front of the plate. Right: back of the plate.
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B. Staphylococcus aureus

Figure 26 shows a template displaying how the Congo Red Plates for the
Staphylococcus aureus bacterium were set up. Figure 26 also shows which treatments
inhibited biofilm formation, that was shown in green. Each of the wells were treated
for 5 minutes with their respective treatments and then incubated overnight. The
results shown in Figure 27 show that the EGCG-S and P-EGCG tea polyphenols have
a synergistic effect when combined with the antibiotics, Polymyxin B and Bacitracin.
Well 5 which is just treated with Polymyxin B alone results in the formation of
biofilm as shown in Figure 27 represented by the color of the well changing to black.
S. aureus is biofilm resistant to Polymyxin B. Though, when S. aureus was treated
with EGCG-S and Polymyxin B combined, it was negative for biofilm shown in Well
8. Wells 15 and 24 which was the treatment of EGCG-S or P-EGCG treated together
with both antibiotic inhibited biofilm formation. Well 16, which was treated with
EGCG-S, wash and both antibiotics together, showed biofilm that formed 24 hours
after incubation, but by 48 hours the biofilm that had formed was started to decrease
as shown in Figure 27.
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Figure 26: Staphylococcus aureus Congo Red Assay plate template. The green
represents the wells which are biofilm negative and do not allow Staphylococcus
aureus to form biofilm with those respective treatments.
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Figure 27: Staphylococcus aureus Congo Red Qualitative Biofilm Assay.
Staphylococcus aureus was treated with various treatments for 5 minutes, as listed in
Figure 26. Two top plates: Congo Red plate 24 hours after treatment. Left: front of
the plate. Right: back of the plate. Bottom two plates: Congo Red plate 48 hours
after treatment. Left: front of the plate. Right: back of the plate.
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C. Staphylococcus epidermidis

Figure 28 shows a template of how the Congo red plate was set up and it also shows
which treatments prevented the formation of biofilm, shown in green. The wells on
the plate were treated for 5 minutes with their respective treatments and then
incubated overnight and analyzed, shown in Figure 29. Wells 5 and 6, which were
treated with Polymyxin B and Bacitracin alone, respectively were positive for biofilm
formation, shown by the black color in Figure 29. S. epidermidis is resistant to both
Polymyxin B and Bacitracin. Though, when EGCG-S was used with either
Polymyxin B or Bacitracin together, wells 8 and 9 respectively, did not result in the
formation of biofilm. This data suggests that the tea polyphenols EGCG-S and PEGCG have a synergistic effect with the antibiotics Polymyxin B and Bacitracin on S.
epidermidis and enhance antimicrobial activity.

JOINT INFECTIONS: EGCG-S AND BACTERIA

58

Figure 28: Staphylococcus epidermidis Congo Red Assay plate template. The green
represents the which treatments are biofilm negative and do not allow Staphylococcus
epidermidis to form biofilm.
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Figure 29: Staphylococcus epidermidis Congo Red Qualitative Biofilm Assay.
Staphylococcus epidermidis was treated with various treatment for 5 minutes, as
shown in Figure 28. Top two plates: Congo Red plate 24 hours after treatment. Left:
front of the plate. Right: back of the plate. Bottom two plates: Congo Red plate 48
hours after treatment. Left: front of the plate. Right: back of the plate.
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D. Combination of Bacteria: Pseudomonas aeruginosa+ Staphylococcus aureus+
Staphylococcus epidermidis

In this Congo Red study with all three of the bacteria combined, EGCG-S and PEGCG tea polyphenols were used to see their effect on the formation of biofilm.
Figure 30 shows a template of how the Congo Red experimental plate was set up and
it also shows which treatments were negative for biofilm and inhibition its formation,
and those treatments are shown in green in Figure 30. The wells on the plate were
treated with their respective treatments for 5 minutes and are shown in Figure 31.
After the plate was incubated, it was qualitatively analyzed. The results shown in
Figure 31 indicate that the EGCG-S and P-EGCG tea polyphenols have a
considerable synergistic effect with the antibiotics, Polymyxin B and Bacitracin on
the combination of the three bacteria together (P. aeruginosa + S. aureus + S.
epidermidis). Wells 5 and 6, which were treated with Polymyxin B and Bacitracin
respectively were positive for biofilm formation and this is represented in Figure 31
with that corresponding well turning black. Though, it was found that when the tea
polyphenol EGCG-S is used in combination with either Polymyxin B or Bacitracin
(wells 14 and 15, respectively), the treatment inhibited the formation of biofilm and
the wells remained red as shown in Figure 31. Wash, Polymyxin B and Bacitracin by
themselves do not work as a treatment since they allow biofilm to form.
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Figure 30: Combination of all three of the bacteria (Pseudomonas aeruginosa,
Staphylococcus aureus and Staphylococcus epidermidis) Congo Red Assay plate
template. The green represents the well which are biofilm negative and do not allow
the combination bacteria to form biofilm with those respective treatments.

JOINT INFECTIONS: EGCG-S AND BACTERIA

62

Figure 31: Combination Bacteria (P. aeruginosa, S. aureus and S. epidermidis)
Congo Red Qualitative Biofilm Assay. The combination bacteria was treated with
various treatments for 5 minutes, which are listed in Figure 30. Top two plates:
Congo Red plate 24 hours after treatment. Left: front of the plate. Right: back of the
plate. Bottom two plates: Congo Red plated 48 hours after treatment. Left: front of
the plate. Right: back of the plate.
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Summary:
The single treatments EGCG-S, P-EGCG and Wash inhibited the formation of
biofilm for P. aeruginosa, S. aureus, and S. epidermidis. The profiling patten is
identical for P. aeruginosa, S. aureus (Figure 24, and Figure 26. The patten is slightly
different for S. epidermidis (Figure 28). Treatment with Bacitracin alone only
inhibited biofilm formation against P. aeruginosa and S. aureus but not for S.
epidermidis. The antibiotic Polymyxin B by itself did not work on any of the
individual bacteria. All of the different combinations of EGCG-S and P-EGCG
combined with Polymyxin B and Bacitracin inhibited biofilm formation of P.
aeruginosa, S. aureus, and S. epidermidis. The combination bacteria showed similar
results (Figure 20) as the individual bacteria, except that the Wash treatment did not
inhibit biofilm formation against it. The reason that the Wash treatment did not work
on the combination bacteria could be because some kind of interaction or competition
could be occurring among these three organisms.

JOINT INFECTIONS: EGCG-S AND BACTERIA

64

Figure 32: Summary of Congo Red Qualitative Biofilm Assay. Summary of how
different treatments against individual bacteria and combination bacteria affect biofilm
formation. PA: Pseudomonas aeruginosa; SA: Staphylococcus aureus; SE:
Staphylococcus epidermidis; Combo: Combination Bacteria (Pseudomonas aeruginosa+
Staphylococcus aureus+ Staphylococcus epidermidis). The (-) represents that biofilm did
not form with the respective treatment. The (+) represents that biofilm formed regardless
of the respective treatment.
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Crystal Violet Quantitative Assay to Analyze the Effect of Tea Polyphenols on
Biofilm Inhibition
A Congo Red qualitative assay tells us if different treatments are able to inhibit the
growth of biofilm. In order to see what percentage of biofilm is inhibited, a Crystal
Violet quantitative assay was carried out.

A. Pseudomonas aeruginosa

In this study, EGCG-S and P-EGCG tea polyphenols as well as the antibiotics,
Polymyxin B and Bacitracin were used to analyze the effect that they have on
biofilm inhibition. Figure 33 shows the experimental plate on the top and the
control well at the bottom. The way the wells are numerically labeled in Figure 33
corresponds to the treatment numbers that are shown in Figure 34. Figure 35
shows the what the negative control plate looked like after the crystal violet
quantitative assay and its corresponding template. Figure 36 shows how the
formation of biofilm was inhibited regarding P. aeruginosa cell cultures after
being treated for 96 hours. The percentage of biofilm inhibition across all the
treatments ranged from 64.70 percent to 99.89 percent. When P. aeruginosa cell
cultures were treated with EGCG-S, Polymyxin B and Bacitracin together, that
resulted in an inhibition of biofilm formation percentage of 99.32 percent. This
treatment represented the second highest inhibition percentage, with the first
highest inhibition percentage represented by bleach at 99.89 percent. When
EGCG-S was used with Polymyxin B together, the percent of inhibition for P.
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aeruginosa increased approximately 16 percent compared to using Polymyxin B
alone as a treatment (98.10 percent versus 82.95 percent).

Figure 33: Pseudomonas aeruginosa Crystal Violet Quantitative Assay
Experimental Plate and Control. Top: Shows the experimental plate. Left- front
of the plate. Right- back of the plate. Bottom: The front and back of the control
well. The well numbers displayed are associated to the treatments shown in
Figure 34.

JOINT INFECTIONS: EGCG-S AND BACTERIA

67
Well 6: EGCG-S+

Well 1: EGCG-S
Polymyxin B
Well 7: EGCG-S+
Well 2: P-EGCG
Polymyxin B+ Bacitracin
Well 3: Bacitracin

Well 8: CF1

Well 4: Polymyxin B

Well 9: CF2

Well 5: EGCG-S+ Bacitracin

Well 10: Bleach

Figure 34: Template of Crystal Violet assay treatment set up.
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Figure 35: Negative Control Plate for the Pseudomonas aeruginosa Crystal
Violet Assay. Top: Front and back of the negative control plate, from left to right
respectively. Bottom: Template of the negative control plate.
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Pseudomonas aeruginosa
Well Number

Treatment

% of Biofilm Inhibition

1

EGCG-S (2.5 mg/mL)

95.11%

2

P-EGCG (2.5 mg/mL)

64.70%

3

Bacitracin (10x)

92.97%

4

Polymyxin B (10x)

82.95%

5

EGCG-S + Bacitracin

90.56%

6

EGCG-S + Polymyxin B

98.10%

7

EGCG-S + Polymyxin B+ Bacitracin

99.32%

8

CF1

94.13%

9

CF2

98.97%

10

Bleach

99.89%

Figure 36: Inhibition of Pseudomonas aeruginosa Cell Cultures after 96 Hour
Treatments. The treatments used involved the EGCG-S and P-EGCG tea
polyphenols as well as Polymyxin B, Bacitracin, CF1 and CF2 formulations and
bleach.
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B. Staphylococcus aureus

Figure 37 shows the experimental plate and the control well. Figure 38 also shows
which treatments were applied to which well. Figure 38 shows how the formation of
biofilm was inhibited regarding S. aureus cell cultures after being treated for 96
hours. The percentage of biofilm inhibition across all of the treatments ranged from
50.69 percent to 99.55 percent. It was shown that EGCG-S works better than PEGCG at inhibiting biofilm formation. When S. aureus was treated with EGCG-S,
Polymyxin B and Bacitracin together, it resulted in an inhibition of biofilm formation
percentage of 68.09 percent. When Bacitracin and Polymyxin B alone were used to
treat S. aureus, the results showed 89.89 percent and 85.77 percent for inhibiting S.
aureus biofilm formation.
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Figure 37: Staphylococcus aureus Crystal Violet Quantitative Assay Experimental
Plate and Control. Top: Shows the experimental plate. Bottom: Shows the control
well. The numbers displayed on the top of wells are associated to the treatments
shown to the right in the figure.
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Figure 38: Inhibition of Staphylococcus aureus Cell Cultures after 96 Hour treatments. The
treatments used involved EGCG-S and P-EGCG tea polyphenols as well as Polymyxin B,
Bacitracin, CF1 and CF2 formulations and bleach.

72

JOINT INFECTIONS: EGCG-S AND BACTERIA

73

C. Staphylococcus epidermidis

EGCG-S and P-EGCG tea polyphenols were used with antibiotics, Polymyxin B and
Bacitracin to analyze the effect that they have on biofilm inhibition. Figure 39 shows
the experimental plate on the top and the control well at the bottom. The percentage
of biofilm inhibition ranged from 25.10 percent to 98.92 percent as shown in Figure
40. EGCG-S was shown to work better than P-EGCG at inhibiting S. aureus biofilm
formation. When S. epidermidis cell cultures were treated with EGCG-S and
Bacitracin together, that resulted in an inhibition of 98.65 percent. This treatment
represented the third highest inhibition percentage, with the first two being bleach and
Bacitracin. The use of EGCG-S with Polymyxin B increases biofilm inhibition by
approximately 11 percent. EGCG-S with single antibiotics (Polymyxin B: 94.16
percent, Bacitracin: 98.65 percent) as treatments work better than EGCG-S with both
antibiotics combined together which resulted in a percent inhibition of 68.86 percent
regarding biofilm formation.
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Figure 39: Staphylococcus epidermidis Crystal Violet Quantitative Assay Experimental
Plate and Control. Top: Shows the experimental plate. Bottom: Shows the control well. The
numbers displayed on the top of the wells are associated to the treatments shown to the right
in the figure.
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Figure 40: Inhibition of Staphylococcus epidermidis Cell Cultures after 96 Hour Treatments.
The treatments used involved the EGCG-S and P-EGCG tea polyphenols as well as Polymyxin
B, Bacitracin, CF1 and CF2 formulations and bleach.
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D. Combination of Bacteria: Pseudomonas aeruginosa+ Staphylococcus aureus+
Staphylococcus epidermidis

EGCG-S and P-EGCG tea polyphenols were used with wash and the antibiotics,
Polymyxin B and Bacitracin to see how they affect the formation of biofilm when
treated against a combination of bacteria, which consists up of P. aeruginosa, S.
aureus and S. epidermidis. Figure 41 shows the experimental crystal violet plate and
a template that shows the treatments that each well was given. When EGCG-S was
used with Polymyxin B together, there was a percent inhibition of 67.58 percent.
Interestingly, when EGCG-S, wash, Polymyxin B and Bacitracin were combined as a
treatment to treat the combination bacteria, 83.89 percent of biofilm formation was
inhibited, shown in Figure 42. The use of antibiotics with EGCG-S and P-EGCG
increases the percent inhibition of biofilm formation, shown in Figures 42 and 43,
respectively. The EGCG-S, Polymyxin B, Bacitracin and Wash combined treatment
worked the best at inhibiting biofilm formation against the combination bacteria.
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Figure 41: Combination Bacteria (Pseudomonas aeruginosa+ Staphylococcus
aureus+ Staphylococcus epidermidis) Crystal Violet Quantitative Assay
Experimental Plate with the template.
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Figure 42: Inhibition of Biofilm Formation of P. aeruginosa, S. aureus and S. epidermidis
Combination Bacterial Cell Cultures after 96 Hour Treatments with EGCG-S, Wash and
Antibiotic Combinations
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Figure 43: Inhibition of Biofilm Formation of P. aeruginosa, S. aureus and S. epidermidis
Combination Bacterial Cell Cultures after 96 Hour Treatments with P-EGCG, Wash and
Antibiotic combinations.
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Summary:

EGCG-S by itself works really well for inhibiting biofilm formation for P. aeruginosa, S. aureus,
and S. epidermidis. Bacitracin works better as a treatment alone than Polymyxin B for all three of
the bacteria, especially for S. epidermidis. For P. aeruginosa, EGCG-S + Polymyxin B+
Bacitracin as a treatment works the best at inhibiting biofilm formation, but not for S. aureus and
S. epidermidis. The single EGCG-S treatment for S. aureus worked better than the combination
treatments with antibiotics. EGCG-S+ Polymyxin B+ Bacitracin+ Wash worked the best for the
combination bacteria.

Figure 44: Summary of Crystal Violet Quantitative Biofilm Assay. PA: Pseudomonas
aeruginosa; SA: Staphylococcus aureus; SE: Staphylococcus epidermidis; Combo: Combination
Bacteria (Pseudomonas aeruginosa+ Staphylococcus aureus+ Staphylococcus epidermidis).
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Discussion
Gram negative bacteria are characterized by having a thin peptidoglycan layer along their cell
wall compared to Gram-positive bacteria, which have a thick peptidoglycan layer. Since Gramnegative bacteria have an outer membrane protecting them along with the peptidoglycan layer,
they are known to be more pathogenic and virulent than Gram-positive bacteria. The reason that
performing a gram stain to differentiate if bacteria of interest is gram-positive or gram-negative
is because treatments could work differently on the two categories of bacteria. DNA extracting,
sequencing and a BLAST search will be performed to confirm the identity of the bacteria.

There are two ways that the tea polyphenols EGCG-S and P-EGCG regarding treating bacterial
infections, either in the wash step or in the antibiotic steps. From this study, it shows that EGCGS and P-EGCG combined with any of the two antibiotics gives promising results, but further
studies will be needed. In order to get a higher efficacy, the concentration of the tea polyphenols
could be increased. A concentration study could be performed in the future going from 250
ߤg/mL to 500 ߤg/mL to see the effectiveness of the green tea polyphenols. Treatments on
Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis individually
showed similar results. The treatments did not work as well on the combination bacteria. The
combination of the three bacteria are harder to treat. This could be due to the interaction and
competition of these microorganisms. 5 ߤL of overnight culture was used for each of the
treatments regarding the individual bacteria. For the combination bacteria, equal volumes of 5 ߤܮ
of overnight culture from each microorganism was mixed into an eppendorf tube and 5 ߤL was
taken out from the eppendorf tube and used for each respective treatment. Since the three
microorganisms could have different generation times, the number of bacterial cells may not be
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the same at the beginning of the treatment. Studies in the future could involve bacterial cell
populations that have identical optical densities. Treatments can be applied to the bacterial cell
populations to see if they are density dependent. A gram stain can also be performed to check the
proportion of rod shaped bacteria to cocci shaped bacteria. This profiling study is the initial step
in searching for the best combination treatments. Further experiments with the best treatment
combinations should be carried out in many repeatings. The multiple readings will allow
statistical analysis to be used to determine the significance of the different treatments.

CF1 and CF2 are very good antimicrobial agents. They are really potent and have a very high
efficacy. Further studies need to be performed to determine the log reduction. A higher density
of cells should be used and with more serial dilutions. Since the CF1 and CF2 formulations have
such a high efficacy, future experiments should be carried out with 1:2, 1:5 and 1:10 dilutions of
these CF1 and CF2 formulations. If lower concentrations of these formulations can obtain the
same results, that will be cost-effective for commercializing these formulations.

A Congo red qualitative assay is fast, and it provides very clear results. All three of the
microorganisms can form biofilm within 24 hours. These microorganisms are very good biofilm
formers. In order to look at their biofilm forming ability, the experiment should be carried out
again and the observation time should be extended from 12 to 96 hours. This study makes it easy
to understand which agents regarding treatments worked. EGCG-S, P-EGCG with antibiotics as
treatments worked at inhibiting biofilm formation against all three bacteria: Pseudomonas
aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis. Also, it is interesting to
work on pre-formed biofilm. It has been reported that pre-formed biofilm are hard to treat with
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antibiotics, so future studies can be focused on that and treating pre-formed biofilm. Even though
the most efficient and effective approach to controlling bacterial infections associated with
biofilms is to inhibit the formation of biofilm, joint prosthetic medical devices that can have
virulent bacterial biofilms on them make it hard to treat the bacterial infections. It has recently
been shown that biofilm can be eliminated by using antibiofilm compounds (Wolfmeier et al.,
2017). Therefore, in order to improve treatment efficacy on persistent biofilms, antibiofilm
compound that have a high bioavailability could be used. Whether or not the synergism of
EGCG-S and antibiotics can extend to interfere with matured biofilms is still elusive and of
interest to further investigate.

The crystal violet quantitative biofilm assay showed that Bacitracin and Polymyxin B alone
worked pretty well against Pseudomonas aeruginosa, Staphylococcus aureus, and
Staphylococcus epidermidis. The EGCG-S, Polymyxin B and Bacitracin combination treatment
worked the best for Pseudomonas aeruginosa bacterial infections, but not for Staphylococcus
aureus and Staphylococcus epidermidis. This could be due to some interaction with the EGCG-S
and antibiotics, so the experiment needs to be repeated a few more times. Performing a crystal
violet biofilm assay is very time consuming and technical. The sides of the wells have to be
cleaned really well otherwise background noise will affect the absorbance reading of the
samples. This quantitative biofilm assay, because of the process can possibly give you very high
standard errors. There are other biofilm assays like the resazurin fluorescence biofilm assay,
which gives better quantitative data, and the background noise is also reduced with this type of
assay. In future studies, a resazurin biofilm assay can be performed with the same treatments
used in the crystal violet biofilm assay and the results can be compared to each other.
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Conclusion
In this study, EGCG derivatives were used to see if they could overcome the antibiotic resistance
problem. EGCG-S and P-EGCG were used in various combinations with wash and the two
antibiotics, Polymyxin B and Bacitracin to see if they can inhibit the growth of Pseudomonas
aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis. With all of the combination
profiling studies that were performed, they suggested that EGCG-S and P-EGCG can enhance
the efficacy of the wash step and the antibiotics (Polymyxin B and Bacitracin) step. The study
indicated that the CF1 and CF2 formulations are excellent antimicrobial agents and they inhibit
the growth of all three of the bacteria in 30 seconds with near 100 percent inhibition and a very
high log reduction. The Congo Red qualitative biofilm assay, which is a combination profiling
study indicated that all of the EGCG-S and P-EGCG containing combination treatments worked.
Polymyxin B did not work on any of the bacteria, and this could be why the current treatment
method is not as effective. The Crystal Violet quantitative biofilm assay showed that EGCG-S
by itself worked really well and that it also worked well with the two antibiotics. This study
shows that the EGCG-S and P-EGCG tea polyphenols can be used as a treatment option against
bacteria that cause joint infections.
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Future Studies
The mechanism in which the EGCG derivatives, EGCG-S and P-EGCG target bacteria and
prevent the formation of biofilm will have to be further researched. This was an initial profiling
study, so the most effective combination treatments will be further analyzed. The Crystal Violet
Biofilm Assay should be carried out again to get conclusive results or another method like a
resazurin assay should also be used to do a quantitative study. The bacteria will have to be
analyzed through PCR as well as observation through a fluorescence microscope. To have a
better understanding of the biofilm involved in the Congo Red Assay, live and dead assays will
need to be performed. In the future, the treatments that were found to be the most effective in this
study should be used on prosthetic joint materials and further analyzed.
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